CEO Magnus Nilsson has the same number of shares as before March 6, 2019

XVIVO Perfusion hereby announces that, after the month's share transactions, CEO Magnus Nilsson has the same number of shares (200,000 shares) as before March 6, 2019. The share transactions during the period 6 to 22 March were a result of the execution of an option program. 

March 25, 2019
XVIVO Perfusion AB (publ)

For further information please contact:

Christoffer Rosenblad, CFO, +46 735 192159,
For further information on XVIVO Perfusion’s business, please refer to the company’s website,

The information was submitted for publication, through the agency of the contact person set out above, at 06:00 am CET on March 25, 2019.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.


XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in Lund, Sweden and one office in Denver, the USA. The XVIVO share is listed on Nasdaq Stockholm and has the ticker symbol XVIVO. More information can be found on the website

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: Website: